ACOLTREMON | N217370 | ALCON LABORATORIES INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Triple Gate Capital, LP FDA-2025-P-5790 · 3 docket documents Triple Gate Capital, LP filed this citizen petition under 21 CFR 10.30 requesting that the FDA modify the prescribing information for TRYPTYR (acoltremon ophthalmic solution), an NDA product, to change the indication from "treatment of the signs and symptoms of dry eye disease" to "indicated to incr | Other | 2025-11-03 | Open | Triple Gate Capital, LP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$14.09
per ea
Lowest NADAC/Unit
$14.09
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00065859502TRYPTYR 0.003% EYE DROP | $14.09 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.